Montelukast Krka

Montelukast, the active ingredient in Montelukast Krka, is a leukotriene receptor antagonist presented as a tablet for oral use. It selectively blocks cysteinyl leukotriene receptors to reduce airway inflammation and bronchoconstriction, and is prescribed for asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in both adults and children under medical supervision.

GNH USA supplies Montelukast Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU manufacturing standards and providing reliable global distribution for qualified healthcare institutions.

Montelukast is a leukotriene receptor antagonist used to manage conditions driven by leukotriene‑mediated inflammation. - Asthma: helps achieve better long‑term control of persistent asthma and decreases the need for rescue inhaler use. - Allergic rhinitis: reduces nasal congestion, sneezing, itching and watery eyes in seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after vigorous physical activity, improving exercise tolerance.

Montelukast may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache reported, usually transient. - Upper respiratory tract infection: symptoms such as sore throat, nasal congestion or mild cough. - Abdominal pain: occasional stomach discomfort or cramping without severe signs. - Diarrhea: intermittent loose stools that resolve without intervention.

Serious or Rare Side Effects: - Mood changes: depression, anxiety, or suicidal thoughts requiring prompt evaluation. - Allergic reactions: rash, itching, swelling, or anaphylaxis that may need emergency care. - Liver enzyme elevation: increased hepatic enzymes indicating possible liver dysfunction.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use. - Indication verification: confirm diagnosis of asthma, allergic rhinitis, or exercise‑induced bronchoconstriction before initiation. - Age considerations: use according to approved pediatric dosing guidelines and monitor growth in children. - Hepatic impairment: assess liver function and adjust therapy if significant hepatic disease is present. - Neuropsychiatric monitoring: observe patients for mood changes, depression, or suicidal ideation during treatment. - Drug interactions: review concomitant medications for potential interactions that may affect efficacy or safety. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture and direct sunlight.

Montelukast can interact with other medicines, influencing its effectiveness or increasing risk of adverse effects.

Major Interactions (Avoid): - Phenobarbital: enzyme induction may reduce montelukast plasma levels, decreasing efficacy. - Rifampin: strong CYP3A4 inducer that can lower therapeutic concentrations.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine, sertraline): may increase risk of neuropsychiatric side effects. - Antifungal agents (e.g., ketoconazole): can modestly raise montelukast levels. - Warfarin: potential for altered anticoagulant effect; monitor INR.